Zidesamtinib & PPIs in Pacific
from OncoPharm Hosted by John Bossaer
A new drug is approved for ROS1 NSCLC after a prior TKI (with some data in patients after 2 TKIs). Zidesamtinib...easy for you to say. Also, a post hoc analysis of PACIFIC provides some of the best evidence yet of the detrimental effect (?) of PPI use prior to ICI use. Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 16 minutes long.
When was this OncoPharm episode published?
This episode was published on July 30, 2026.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.